InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

- Current share price for MYX : $3.150

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$256 Mayne Pharma reports unaudited 3Q FY26 results 29 Apr 2026 9:33AM $2.690 $3.150 risen by 17.10%
$256 MYX expects no material impact from US s232 tariffs 7 Apr 2026 9:41AM $2.330 $3.150 risen by 35.19%
$256 Non-Executive Director retirement and recruitment 2 Apr 2026 12:33PM $2.395 $3.150 risen by 31.52%
$256 Ceasing to be a substantial holder 31 Mar 2026 4:38PM $2.270 $3.150 risen by 38.77%
$256 Becoming a substantial holder 27 Mar 2026 4:46PM $2.280 $3.150 risen by 38.16%
$256 Mayne Pharma ASX SMIDcaps conference presentation 25 Mar 2026 11:12AM $2.300 $3.150 risen by 36.96%
$256 Becoming a substantial holder 24 Mar 2026 5:32PM $2.250 $3.150 risen by 40%
$256 Ceasing to be a substantial holder 23 Mar 2026 4:45PM $2.220 $3.150 risen by 41.89%
$256 Mayne Pharma to present at ASX SMIDcaps Conference 17 Mar 2026 9:00AM $2.320 $3.150 risen by 35.78%
$256 DistributeRx Launch Investor Presentation 11 Mar 2026 9:22AM $2.470 $3.150 risen by 27.53%
$256 Mayne Pharma launches DistributeRx in the US 10 Mar 2026 10:05AM $2.360 $3.150 risen by 33.47%
$256 Becoming a substantial holder 9 Mar 2026 6:01PM $2.340 $3.150 risen by 34.62%
$256 S&P DJI Announces March 2026 Quarterly Rebalance 6 Mar 2026 5:05PM $2.540 $3.150 risen by 24.02%
$256 Becoming a substantial holder 3 Mar 2026 8:26AM $2.450 $3.150 risen by 28.57%
$256 Ceasing to be a substantial holder from MUFG 2 Mar 2026 6:40PM $2.450 $3.150 risen by 28.57%
$256 Final Director's Interest Notice (x2) 2 Mar 2026 2:39PM $2.465 $3.150 risen by 27.79%
$256 Ceasing to be a substantial holder 27 Feb 2026 5:56PM $2.520 $3.150 risen by 25%
$256 Proposed issue of securities - MYX 23 Feb 2026 6:56PM $2.610 $3.150 risen by 20.69%
$256 Final Director's Interest Notice 23 Feb 2026 6:51PM $2.610 $3.150 risen by 20.69%
$256 2026 Half Year Investor Presentation 23 Feb 2026 9:38AM $2.650 $3.150 risen by 18.87%
$256 2026 Half Year Media Release 23 Feb 2026 9:35AM $2.650 $3.150 risen by 18.87%
$256 Half Yearly Report and Accounts 23 Feb 2026 9:34AM $2.650 $3.150 risen by 18.87%
$256 Mayne Pharma Management Changes 23 Feb 2026 9:31AM $2.650 $3.150 risen by 18.87%
$256 Notification of date for release of 1H26 results 19 Feb 2026 2:03PM $2.645 $3.150 risen by 19.09%
$256 MYX to claim against Cosette, Avista & Mr David Burgstahler 18 Feb 2026 9:35AM $2.650 $3.150 risen by 18.87%

26 - 50 of 887 results

Page 2 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.